PWM
MRKR icon

Prentice Wealth Management’s Marker Therapeutics MRKR Stock Holding History

Prentice Wealth Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-125
Closed -$2K – 228
2021
Q3 		$2K Hold
125
– – ﹤0.01% 301
2021
Q2 		$3K Hold
125
– – ﹤0.01% 283
2021
Q1 		$3K Buy
+125
New +$2.86K ﹤0.01% 288

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prentice Wealth Management's MRKR Position: Q4 2021 in Review

Prentice Wealth Management sold out of Marker Therapeutics (MRKR) in Q4 2021, closing a stake of 125 shares — an estimated $2K sold.

Prentice Wealth Management first reported a position in MRKR in Q1 2021 and held it in 3 quarters. The position peaked at $3K in Q2 2021. 64 funds tracked by Wall St. Rank hold MRKR as of Q4 2021.

  • Prentice Wealth Management reported no remaining Marker Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Prentice Wealth Management sold 125 Marker Therapeutics shares in Q4 2021, an estimated $2K.
  • Prentice Wealth Management first reported a position in Marker Therapeutics in Q1 2021 and held it in 3 quarters.
  • Prentice Wealth Management's Marker Therapeutics position peaked at $3K in Q2 2021.
  • 64 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2021.

Based on Prentice Wealth Management's 13F filing for Q4 2021, filed 31 Oct 2022.